1,4-二甲基-1H-吡咯并[3,2-c]吡啶 | 102839-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1,4-二甲基-1H-吡咯并[3,2-c]吡啶
• 英文名称: 1,4-dimethyl-1H-pyrrolo<3,2-c>pyridine
• 英文别名: 1,4-dimethyl-1H-pyrrolo[3,2-c]pyridine；1,4-dimethylpyrrolo[3,2-c]pyridine
• CAS: 102839-50-9
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: XIOMPJOLMMKSKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,4-二甲基-1H-吡咯并[3,2-c]吡啶 生成 bis(1,4-dimethyl-1H-pyrrolo<3,2-c>pyrid-3-yl)methane
  参考文献：
  名称：

  CASY, A. F.;NEEDLE, R. J.;UPTON, C., J. CHEM. RES. SYNOP., 1986, N 1, 4

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-氨基乙基)-1-甲基吡咯烷 在 palladium on activated charcoal polyphosphate ester 、 三乙胺 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 9.0h， 生成 1,4-二甲基-1H-吡咯并[3,2-c]吡啶
  参考文献：
  名称：

  Casy, Alan F.; Needle, Richard J.; Upton, Christopher, Journal of Chemical Research, Miniprint, 1986, # 1, p. 343 - 360

  摘要：

  DOI：

文献信息

• ORGANIC LIGHT-EMITTING DIODE MATERIALS
  申请人：President and Fellows of Harvard College

  公开号：US20180212158A1

  公开（公告）日：2018-07-26

  Described herin are molecules for use in organic light emitting diodes. Example molecules comprise at least one acceptor moiety A, at least one donor moiety D, and optionally one or more bridge moieties B. Each moiety A is covalently attached to either the moiety B or the moeity D, each moiety D is covalently attached to either the moeity B or the moeity A, and each B is covalently attached to at least one moiety A and at least one moiety D. Values and preferred values of moieties A, D and B are defined herein.

  本文描述了用于有机发光二极管的分子。示例分子包括至少一个受体基团A，至少一个给体基团D，以及可选地一个或多个桥接基团B。每个基团A与基团B或基团D中的任一基团共价连接，每个基团D与基团B或基团A中的任一基团共价连接，每个基团B与至少一个基团A和至少一个基团D共价连接。这里定义了基团A、D和B的值和首选值。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：PHARMACYCLICS, INC.

  公开号：US20150265618A1

  公开（公告）日：2015-09-24

  Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

  本文描述了不可逆激酶抑制剂化合物，合成这种不可逆抑制剂的方法，以及使用这种不可逆抑制剂治疗疾病的方法。此外，本文还描述了用于确定蛋白质（包括激酶）适当的不可逆抑制剂的方法、测定和系统。
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20220332713A1

  公开（公告）日：2022-10-20

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.
• US8450343B2
  申请人：——

  公开号：US8450343B2

  公开（公告）日：2013-05-28
• [EN] MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020065613A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.